Insider Buying: DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Major Shareholder Purchases 1,200,000 Shares of Stock

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) major shareholder Koch Thomas Von acquired 1,200,000 shares of the business’s stock in a transaction dated Friday, June 28th. The stock was acquired at an average price of $2.50 per share, for a total transaction of $3,000,000.00. Following the purchase, the insider now directly owns 5,526,435 shares of the company’s stock, valued at $13,816,087.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

DiaMedica Therapeutics Price Performance

NASDAQ:DMAC opened at $2.80 on Wednesday. The company has a 50 day moving average price of $2.79 and a 200-day moving average price of $2.82. DiaMedica Therapeutics Inc. has a 1-year low of $1.94 and a 1-year high of $4.45. The firm has a market cap of $106.29 million, a price-to-earnings ratio of -5.00 and a beta of 1.49.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. On average, sell-side analysts anticipate that DiaMedica Therapeutics Inc. will post -0.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DMAC has been the topic of several recent research reports. Oppenheimer reaffirmed an “outperform” rating and issued a $6.00 price target (down from $7.00) on shares of DiaMedica Therapeutics in a report on Thursday, March 21st. Craig Hallum assumed coverage on DiaMedica Therapeutics in a research note on Wednesday, April 24th. They issued a “buy” rating and a $8.00 target price on the stock.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in DiaMedica Therapeutics by 26.3% in the first quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock valued at $2,807,000 after purchasing an additional 211,351 shares during the period. Paragon Associates & Paragon Associates II Joint Venture lifted its position in shares of DiaMedica Therapeutics by 6.4% during the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock valued at $1,420,000 after buying an additional 30,000 shares in the last quarter. Stonebridge Capital Advisors LLC acquired a new stake in DiaMedica Therapeutics in the 3rd quarter valued at $52,000. Finally, Avantax Advisory Services Inc. acquired a new stake in DiaMedica Therapeutics in the 4th quarter valued at $36,000. Hedge funds and other institutional investors own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.